Patents by Inventor Miguel Jimenez
Miguel Jimenez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11899014Abstract: The present invention provides sensor cells comprising a receptor that binds to an analyte indicative of the presence of an agent, where binding of the analyte to the receptor triggers a detection event that is indicative of the presence of the agent. In certain embodiments, the detection event is appearance of a reporter detectable by the naked eye. The present invention also provides uses of such sensor cells for detecting the presence of an agent in a sample.Type: GrantFiled: June 19, 2020Date of Patent: February 13, 2024Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Virginia Wood Cornish, Nili Ostrov, Miguel Jimenez, Sonja Billerbeck
-
Publication number: 20230297366Abstract: Disclosed are techniques for two-way synchronization of infrastructure-as-code templates and instances, including a method comprising detecting changes to a run-time state of a system and, in response to detecting a change, triggering an update of a current run-time state model. The method may further comprise, in response to updating the run-time state model, comparing the updated model to a current model using a template in a local repository instantiated as the current model. The method may further comprise, in response to the comparison determining a structural difference between the updated model and the current model, merging the updated model and the current model into a new model; and updating a local clone of a repository of the template with the new model. The method may further comprise, in response to the comparison determining no structural difference between the updated model and the current model, pushing changes to a remote repository.Type: ApplicationFiled: March 18, 2022Publication date: September 21, 2023Inventors: Joseph Paul Wigglesworth, Miguel Jimenez, Gabriel Tamura, Hans Albert Muller, Ian Fraser Watts, Hugh Edward Hockett
-
Publication number: 20230271963Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.Type: ApplicationFiled: June 23, 2022Publication date: August 31, 2023Inventors: Nadia AHMAD, Dean BOYALL, Jean-Damien CHARRIER, Chris DAVIS, Rebecca DAVIS, Steven DURRANT, Gorka ETXEBARRIA I JARDI, Damien FRAYSSE, Juan-Miguel JIMENEZ, David KAY, Ronald KNEGTEL, Donald MIDDLETON, Michael O'DONNELL, Maninder PANESAR, Francoise PIERARD, Joanne PINDER, David SHAW, Pierre-Henri STORCK, John STUDLEY, Heather TWIN
-
Publication number: 20220378363Abstract: Transient molecules in the gastrointestinal (GI) tract, such as nitric oxide and hydrogen sulfide, are important signals and mediators of inflammatory bowel disease (IBD). Because these molecules may be short-lived in the body, they are difficult to detect. To track these reactive molecules in the GI tract, a miniaturized device has been developed that integrates genetically engineered probiotic biosensors with a custom-designed photodetector and readout chip. Leveraging the molecular specificity of living sensors, bacteria were genetically encoded to respond to IBD-associated molecules by luminescing. Low-power electronic readout circuits (e.g., using nanowatt power) integrated into the device convert the light from just 1 ?L of bacterial culture into a wireless signal. Biosensor monitoring was demonstrated in the GI tract of small and large animal models and integration of all components into a sub-1.4 cm3 ingestible form factor capable of supporting wireless communication.Type: ApplicationFiled: April 26, 2022Publication date: December 1, 2022Applicants: Massachusetts Institute of Technology, Trustees of Boston University, The Brigham and Women's Hospital, Inc.Inventors: Timothy Kuan-Ta Lu, Rabia Tugce Yazicigil Kirby, Carlo Giovanni Traverso, Jenna Ahn, Maria Eugenia Inda, Miguel Jimenez, Qijun Liu, Phillip Nadeau, Christoph Winfried Johannes Steiger, Adam Wentworth
-
Patent number: 11376294Abstract: A method for enhancing at least one of alertness, attention, concentration and memory in a person in need thereof, comprising co-administering an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; and caffeine to the person. The components may be co-administered in a single composition, or administered in separate compositions. The mangiferin and/or norathyriol exhibit synergistic effects on brain wave activity when co-administered with caffeine.Type: GrantFiled: March 26, 2019Date of Patent: July 5, 2022Assignee: NEKTIUM PHARMA S.L.Inventors: Miguel Jimenez del Rio, Julia C. Wiebe, Laura Lopez-Rios, Tanausu Vega-Morales, Ruben Perez-Machin, Alvaro Sanchez-Rodriquez, Carlos J. Mateos, Nigel Peter Gericke
-
Patent number: 11370798Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.Type: GrantFiled: August 31, 2020Date of Patent: June 28, 2022Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Nadia Ahmad, Dean Boyall, Jean-Damien Charrier, Chris Davis, Rebecca Davis, Steven Durrant, Gorka Etxebarria I Jardi, Damien Fraysse, Juan-Miguel Jimenez, David Kay, Ronald Knegtel, Donald Middleton, Michael O'Donnell, Maninder Panesar, Francoise Pierard, Joanne Pinder, David Shaw, Pierre-Henri Storck, John Studley, Heather Twin
-
Publication number: 20220132817Abstract: The present invention relates to a non-human mammalian animal which has been modified to have in the blood, plasma and/or serum (a) an increased number of leukocytes and/or neutrophils, and (b) a reduced activity of the DNase 1 and/or DNase 1-like 3 enzymes. The non-human mammalian animal is particularly suitable for studying inflammation and/or a disease associated with inflammation. In a further aspect, the invention relates to the use of the non-human mammalian animal as a model for identifying therapeutic or diagnostic targets of inflammation and/or a disease associated with inflammation. In a still further aspect, the invention relates the use of the non-human mammalian animal as a model for drug candidate testing. In addition, a method for testing an anti-inflammatory drug candidate against extracellular DNA is provided. Finally, a method for testing an anti-inflammatory drug candidate for modifying the formation or degradation of neutrophil extracellular traps is provided.Type: ApplicationFiled: January 10, 2022Publication date: May 5, 2022Inventors: Tobias FUCHS, Miguel JIMENEZ-ALCAZAR, Chandini RANGASWAMY
-
Patent number: 11318293Abstract: A platform technology has been designed to provide a means for controlled delivery of single or multiple doses of therapeutic, prophylactic, diagnostic or identifying agents to livestock. The delivery system is based on a livestock ear tag that releases therapeutic and/or prophylactic agent when applied to the ear or other desired anatomical target of the animal. The agent to be delivered is encapsulated in or on microneedles and or microparticles and or nanoparticles or combination thereof on a surface thereon of the male or female part of the tag, which is pressed into the skin so that the microneedles penetrate into the epidermis and dermis layers of the skin. The agent is then released into the animal from the microneedles and or microparticles and or nanoparticles or combination thereof at the site of contact into the epidermis and dermis layers of the skin.Type: GrantFiled: November 26, 2019Date of Patent: May 3, 2022Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Michael S. Williams, Jason Siu Wei Li, Jacob Coffey, Christoph Winfried Johannes Steiger, Miguel Jimenez, Robert S. Langer, Ester Caffarel Salvador, Alex Abramson, Carlo Giovanni Traverso
-
Publication number: 20220119825Abstract: The present disclosure relates to intercellular signaling between genetically-engineered cells and, more specifically, to a scalable peptide-GPCR intercellular signaling system. The present disclosure provides an intercellular signaling system that includes at least two cells that have been genetically-engineered to communicate with each other, methods of use and kits thereof.Type: ApplicationFiled: October 29, 2021Publication date: April 21, 2022Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Virginia Cornish, James Brisbois, Sonja Billerbeck, Miguel Jimenez
-
Publication number: 20220023376Abstract: At least one of alertness, attention, focus and concentration may be enhanced in a person in need thereof, by a method including a step of administering a composition to the person, where the composition includes: a) between 20 mg and 5 g per dose of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol sufficient to provide between 20 mg and 5 g mangiferin or norathyriol per dose, wherein said extract comprising mangiferin or norathyriol is a mangiferin-containing extract of a plant species in a genus selected from the group consisting of Mangifera, Salacia, Cyclopia, Hypericum, Canscora, Fagraea, Gentiana, Hoppea, Swertia, Hypericum, Polygala, Zizyphus, and mixtures thereof; and b) caffeine.Type: ApplicationFiled: September 24, 2021Publication date: January 27, 2022Inventors: Rubén PÉREZ MACHÍN, Carlos J. MATEOS, Julia C. WIEBE, Tanausú VEGA MORALES, Laura LÓPEZ RÍOS, Miguel JIMÉNEZ DEL RÍO, Nigel Peter GERICKE, Álvaro SÁNCHEZ RODRÍGUEZ
-
Publication number: 20220023327Abstract: The present invention refers to a formulation for increasing sports performance and to a method for increasing sports performance, comprising administering said formulation to an athlete.Type: ApplicationFiled: December 7, 2018Publication date: January 27, 2022Inventors: Julia C. WIEBE, Miguel JIMÉNEZ DEL RÍO, Nigel GERICKE, Jose CALBET
-
Publication number: 20210364523Abstract: The disclosed subject matter relates to nucleic acid constructs that encode one or more fluorescent proteins, which can function as intracellular fluorescent tags, specifically for flow cytometry and fluorescence microscopy. The present disclosure further provides genetically-engineered cells that include one or more nucleic acid constructs and methods for using such genetically-engineered cells and nucleic acid constructs.Type: ApplicationFiled: June 14, 2021Publication date: November 25, 2021Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Andrew V. Anzalone, Virginia W. Cornish, Miguel Jimenez
-
Publication number: 20210342854Abstract: A system and method for assisting a service provider in explaining clauses of an agreement and generating an online agreement. The method includes the steps of providing a consumer interface to the consumer, the consumer interface presents the clauses to the consumer in text and audio form and can receive acceptance or rejection of the consumer in both click gesture and audio from the consumer. The video and audio can be recorded of the steps of presenting the clauses and receiving the response from the consumer.Type: ApplicationFiled: July 13, 2021Publication date: November 4, 2021Inventor: Miguel Jimenez
-
Patent number: 11141450Abstract: A method for enhancing at least one of craving-reduction, mood improvement, avoidance of depression, prevention of weight gain post weight-loss from dieting, reduction of negative side effects produced by anti-appetite drugs and smoke-cessation and promotion of healthy ageing in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b). The composition may comprise a third active ingredient in combination with the Cyperus esculentus extract and mangiferin or norathyriol.Type: GrantFiled: January 10, 2018Date of Patent: October 12, 2021Assignee: NEKTIUM PHARMA, S.L.Inventors: Miguel Jiménez del Río, Julia C. Wiebe, Laura López-Ríos, Tanausú Vega Morales, Rubén Peréz Machín, Alvaro Sánchez Rodríguez, Carlos J. Mateos, Nigel Peter Gericke
-
Patent number: 11117900Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.Type: GrantFiled: August 6, 2019Date of Patent: September 14, 2021Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Nadia Ahmad, Dean Boyall, Jean-Damien Charrier, Chris Davis, Rebecca Davis, Steven Durrant, Gorka Etxebarria I Jardi, Damien Fraysse, Juan-Miguel Jimenez, David Kay, Ronald Knegtel, Donald Middleton, Michael O'Donnell, Maninder Panesar, Francoise Pierard, Joanne Pinder, David Shaw, Pierre-Henri Storck, John Studley, Heather Twin
-
Publication number: 20210277372Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.Type: ApplicationFiled: March 5, 2021Publication date: September 9, 2021Inventors: Tobias A. FUCHS, Miguel JIMÉNEZ-ALCÁZAR, Josephine GÖBEL, Hanna ENGLERT
-
Patent number: 11046942Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.Type: GrantFiled: September 11, 2020Date of Patent: June 29, 2021Assignee: NEUTROLIS, INC.Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
-
Patent number: 11046943Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.Type: GrantFiled: October 12, 2020Date of Patent: June 29, 2021Assignee: NEUTROLIS, INC.Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
-
Publication number: 20210047333Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.Type: ApplicationFiled: August 31, 2020Publication date: February 18, 2021Inventors: Nadia AHMAD, Dean BOYALL, Jean-Damien CHARRIER, Chris DAVIS, Rebecca DAVIS, Steven DURRANT, Gorka ETXEBARRIA I JARDI, Damien FRAYSSE, Juan-Miguel JIMENEZ, David KAY, Ronald KNEGTEL, Donald MIDDLETON, Michael O'DONNELL, Maninder PANESAR, Francoise PIERARD, Marie, Joanne PINDER, David SHAW, Pierre-Henri STORCK, John STUDLEY, Heather TWIN
-
Publication number: 20210040461Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.Type: ApplicationFiled: October 12, 2020Publication date: February 11, 2021Inventors: Tobias A. FUCHS, Miguel JIMÉNEZ-ALCÁZAR, Josephine GÖBEL, Hanna ENGLERT